Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics and keeping the price target at $102.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Viking Therapeutics’ VK2735. The recent data presented at ObesityWeek 2025 underscores VK2735’s efficacy not only in weight loss but also in improving broader metabolic health. The rapid reversal rates of prediabetes and metabolic syndrome within a short 13-week period are particularly noteworthy, suggesting a compelling advantage over existing treatments like tirzepatide and semaglutide, which show benefits over a longer duration.
Moreover, the Phase 2 VENTURE study’s exploratory analysis revealed significant improvements in various cardiometabolic parameters, such as waist circumference, blood pressure, cholesterol, and triglycerides. These findings suggest that VK2735 has the potential to secure a strong commercial position if the results are replicated in the upcoming Phase 3 VANQUISH program. Overall, these positive outcomes support the stock’s potential upside, justifying the Buy rating.
According to TipRanks, Pantginis is a 3-star analyst with an average return of 2.2% and a 44.09% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Celldex, Lexicon Pharmaceuticals, and Travere Therapeutics.